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ABSTRACT
Objectives: A recent update of the definition of acute
respiratory distress syndrome (ARDS) proposed an
empirical classification based on ratio of arterial partial
pressure of oxygen to fraction of inspired oxygen
(PaO2/FiO2) at ARDS onset. Since the proposal did not
mandate PaO2/FiO2 calculation under standardised
ventilator settings (SVS), we hypothesised that a
stratification based on baseline PaO2/FiO2 would not
provide accurate assessment of lung injury severity.
Design: A prospective, multicentre, observational study.
Setting: A network of teaching hospitals.
Participants: 478 patients with eligible criteria for
moderate (100<PaO2/FiO2≤200) and severe (PaO2/
FiO2≤100) ARDS and followed until hospital discharge.
Interventions:We examined physiological and
ventilator parameters in association with the PaO2/FiO2 at
ARDS onset, after 24 h of usual care and at 24 h under a
SVS. At 24 h, patients were reclassified as severe,
moderate, mild (200<PaO2/FiO2≤300) ARDS and non-
ARDS (PaO2/FiO2>300).
Primary and secondary outcomes: Group severity
and hospital mortality.
Results: At ARDS onset, 173 patients had a PaO2/
FiO2≤100 but only 38.7% met criteria for severe ARDS at
24 h under SVS. When assessed under SVS, 61.3% of
patients with severe ARDS were reclassified as moderate,
mild and non-ARDS, while lung severity and hospital
mortality changed markedly with every PaO2/FiO2
category (p<0.000001). Our model of risk stratification
outperformed the stratification using baseline PaO2/FiO2
and non-standardised PaO2/FiO2 at 24 h, when analysed
by the predictive receiver operating characteristic (ROC)
curve: area under the ROC curve for stratification at
baseline was 0.583 (95% CI 0.525 to 0.636), 0.605
(95% CI 0.552 to 0.658) at 24 h without SVS and 0.693
(95% CI 0.645 to 0.742) at 24 h under SVS
(p<0.000001).
Conclusions: Our findings support the need for patient
assessment under SVS at 24 h after ARDS onset to
assess disease severity, and have implications for the
diagnosis and management of ARDS patients.
Trial registration numbers: NCT00435110 and
NCT00736892.
INTRODUCTION
Acute respiratory distress syndrome (ARDS)
is an inﬂammatory process of the lungs
resulting in increased permeability and sub-
sequent interstitial and alveolar protein-rich
oedema.1 ARDS is characterised by severe
hypoxaemia, reduced lung compliance and
bilateral radiographic pulmonary inﬁltrates.1 2
Patients with ARDS require mechanical venti-
lation (MV) with positive end-expiratory pres-
sure (PEEP) for decreasing the work of
breathing and for improving oxygenation.
Current hospital mortality approximates
40–50% in major epidemiological series.3 4
Since diagnosis is based on a combination
of clinical, radiographic and physiologic
Strengths and limitations of this study
▪ Our risk stratification approach has potential
implications for diagnosis, for guiding therapy
and for future design of clinical trials in patients
with acute respiratory distress syndrome
(ARDS).
▪ We cannot expect that our approach for risk
stratification will hold for patients ventilated in a
non-lung protective manner since it is clear that
ventilation with large tidal volumes and high end-
inspiratory plateau pressures cause ventilator-
induced lung injury in addition to the pre-
existing ARDS.
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criteria, these criteria allow the inclusion of a diverse
group of patients. The original description of ARDS was
incapable of identifying a uniform group of patients.5 A
precise deﬁnition is crucial since the effects on outcome
of MV and adjunctive techniques depend on the degree
of lung injury.6 In 1994, an American-European
Consensus Conference (AECC)7 formalised the diagnos-
tic criteria for ARDS and acute lung injury (ALI) but
these deﬁnitions have been challenged over the years.8 9
In 2012, a proposal for updating the ARDS deﬁnition
(the Berlin criteria) was published.10 Three ratio of
arterial partial pressure of oxygen to fraction of inspired
oxygen (PaO2/FiO2) cut-off values recorded at ARDS
onset: severe (≤100 mm Hg), moderate (>100−≤200)
and mild (>200−≤300), were proposed. By only consid-
ering patients who were on PEEP≥5 cm H2O at the time
of study enrolment, the panel found that hospital mor-
tality increased with every stage of PaO2/FiO2 severity.
Since the Berlin criteria, similar to the AECC criteria,
did not mandate the assessment of hypoxaemia under
standardised ventilator conditions, we hypothesised that
PaO2/FiO2 values recorded at ARDS onset or at 24 h
without standardisation of ventilatory management
would not provide accurate assessment of ARDS severity.
To test our hypothesis, we sought to characterise 478
consecutive patients with ARDS, most of them enrolled
in two published multicentre observational studies,9 11
using the Berlin criteria at ARDS onset and reassessed
after 24 h of routine clinical care and at 24 h under stan-
dardised levels of PEEP and FiO2.
METHODS
Data were derived from patients included in two inde-
pendent, multicentre, observational cohorts that enrolled
consecutive patients from 2004 to 2005 and from 2008 to
2010 in a network of intensive care units (see online sup-
plementary appendix), under the Spanish Initiative for
Epidemiology, Stratiﬁcation and Therapies of ARDS
(SIESTA) Program, as described previously.9 11
Study participants
Patients meeting criteria for ARDS using the AECC deﬁn-
ition7 were considered for enrolment in the parent
studies.9 11 Since all patients were on PEEP≥5 at study
entry, they also met the recent Berlin criteria for moder-
ate and severe ARDS.10 Although patient care was not
strictly protocolised, physicians were asked to follow
current standards for critical care management. For ven-
tilatory management, it was recommended that patients
be ventilated with a tidal volume (VT) of 5–8 mL/kg pre-
dicted body weight (PBW), at a ventilatory rate to main-
tain PaCO2 at 35–50 mm Hg, a plateau pressure
<30 cm H2O, and PEEP and FiO2 combinations to main-
tain PaO2 >60 mm Hg or SpO2 >90%. During the enrol-
ment period, none of the patients were included in any
other clinical trial or managed with prone ventilation,
high frequency ventilation or extracorporeal life support.
For the present study, onset of ARDS was deﬁned as the
day and time in which the patient ﬁrst met ARDS criteria.
Demographics, arterial blood gases, radiographic,
haemodynamic and ventilator data were collected at
study entry, at 24 h, at days 3, 7, 14 and last day of MV. ALI
severity score12 and ventilator-free days (VFDs), were cal-
culated and recorded. Total number of extrapulmonary
organ failures included in the Sequential Organ Failure
Assessment (SOFA) scale13 was documented daily.
Patients were followed-up until hospital death or dis-
charge. Approximately 24 h after meeting moderate/
severe ARDS criteria, oxygenation was assessed under the
following standardised ventilator settings (SVS):
VT=7 mL/kg PBW, PEEP=10 cm H2O and FiO2=0.5.
When patients required PEEP>10 or FiO2>0.5 and could
not tolerate a decrease in PEEP or FiO2 for maintaining
the oxygenation target, a set of rules for setting PEEP
and FiO2 were applied only during the SVS assessment
(table 1). At other times, the PEEP and FiO2 levels were
up to the discretion of the managing clinician. Blood
gases were obtained 30 min after the setting adjustment.
Based on the PaO2/FiO2 ratio at study entry, patients
were categorised as moderate or severe ARDS according
to the Berlin criteria. Based on PaO2/FiO2 values at 24 h,
patients were reclassiﬁed into four groups: severe ARDS
(PaO2/FiO2 ≤100 mm Hg), moderate ARDS (100<PaO2/
FiO2≤200), mild ARDS (200<PaO2/FiO2≤300) and
non-ARDS (PaO2/FiO2>300).
Outcome data
We sought to determine whether the use of the baseline
PaO2/FiO2 for stratifying patients at ARDS onset results
in the identiﬁcation of subgroups of patients with a dis-
tinct degree of lung injury. We also examined whether
Table 1 Rules for setting PEEP and FiO2 during
assessment on standardised settings at 24 h of ARDS
diagnosis
PEEP level before
changing to standardised
settings
PEEP setting for
assessment
≤10 cm H2O 10 cm H2O
>10 and <13 cm H2O Set at 10 cm H2O, unless
SpO2<88%. Then returned
to previous level
≥13 cm H2O Maintain current level and
assess
FiO2 level before changing
to standardised settings
FiO2 setting for
assessment
≤0.5 0.5
>0.5 and ≤0.6 Set at 0.5, unless
SpO2<88%. Then, returned
to previous level
>0.6 Maintain current level and
assess
ARDS, acute respiratory distress syndrome; PEEP, positive
end-expiratory pressure.
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patients categorised as severe or moderate ARDS based
on their baseline PaO2/FiO2 could evolve to less severe
forms of lung injury after 24 h of usual care. In addition,
we determined whether the stratiﬁcation of patients
after 24 h of routine clinical care or at 24 h under SVS
could identify groups of patients for each PaO2/FiO2
category with different severity and hospital mortality.
Statistical analysis
Data are expressed as percentage, mean±SD, or median
and IQR. Differences between categorical variables were
analysed by χ2 or Fisher’s exact tests. For continuous vari-
ables, data were analysed using the t test, analysis of vari-
ance, Mann-Whitney or the Kruskall-Wallis tests,
depending on their distribution and number of variables.
To assess the agreement of patient classiﬁcation between
baseline (Berlin criteria) and the stratiﬁcation at 24 h
under standardised ventilator settings, the Cohen’s κ
coefﬁcient (κ) was calculated for severe and moderate
ARDS. We determined the predictive hospital mortality
receiver operating characteristic (ROC) curve using the
values of PaO2/FiO2 ratio in each patient and compared
the overall performance of our model of stratiﬁcation at
24 h of ARDS onset under SVS with the classiﬁcation at
baseline and at 24 h under non-standardised measure-
ment of PaO2/FiO2 ratio. A p value <0.05 was considered
statistically signiﬁcant (two tailed). All statistical analyses
were conducted using SPSS V.20.
RESULTS
Although the published parent studies enrolled 452
patients, the present study included 26 additional
patients who had been enrolled at the time of ﬁnalisa-
tion of both observational periods and were followed-up
until hospital discharge. Thus, the present analysis
included a total of 478 patients with ARDS with com-
plete data.
Baseline characteristics of patients are displayed in
table 2. Pneumonia, sepsis and trauma were the most
common causes of ARDS. No signiﬁcant differences were
found in ventilation and oxygenation parameters at study
entry between survivors and non-survivors, although non-
survivors were older, had a higher APACHE II score and
more organ dysfunctions (table 3). The overall hospital
mortality was 42.2% (95% CI 37.8% to 46.6%). At study
entry, most patients (305/478, 63.8%) had a baseline
PaO2/FiO2>100 mm Hg but their FiO2 and PEEP levels
varied widely ranging from 0.4 to 1.0 and from 5 to
20 cm H2O, respectively. Although patients initially cate-
gorised as severe ARDS had a higher overall hospital mor-
tality than patients classiﬁed as moderate ARDS: 93/173
(53.7%, 95% CI 46.2% to 61.1%) vs 109/305 (35.7%,
95% CI 30.5% to 41.3%) (p=0.002), there were no signiﬁ-
cant differences in lung injury score, PEEP, VT and
number of failing organs between severe and moderate
ARDS when patients were classiﬁed using baseline PaO2/
FiO2 (table 4).
At 24 h of usual clinical care, PaO2 values recorded by
physicians were also measured under a wide range of
FiO2 (0.3–1) and PEEP [0 (only temporarily in 2
patients with bronchopleural ﬁstula) to 22 cm H2O].
Based on those values, patients with a PaO2/FiO2≤100
had a hospital mortality of 53.0%, patients with a
100<PaO2/FiO2<200 had a mortality of 39.8%, patients
with a 200<PaO2/FiO2<300 had a mortality of 39.8%
and those with a PaO2/FiO2>300 had a mortality of
16.7% (p=0.064). When patients were reassessed under
the SVS used in our study, PaO2/FiO2 values changed
and moved patients from one category to another.
Despite 173 patients having a PaO2/FiO2≤100 mm Hg
at ARDS onset, only 38.7% of them maintained the
PaO2/FiO2≤100 mm Hg when assessed at 24 h under
SVS (ﬁgure 1). Most patients diagnosed as severe ARDS
by the Berlin criteria (106/173, 61.3%) were reclassiﬁed
as moderate, mild and non-ARDS, when assessed after
24 h. Only 114 (23.8%) patients could not have their
PEEP or FiO2 level decreased to 10 cm H2O and 0.5 at
the time of assessment, and their assignment was based
on the PaO2/FiO2 value under the clinician-selected
PEEP and FiO2 settings. Cohen’s κ analysis showed a
very high disagreement between a patient’s classiﬁcation
using Berlin criteria and assessment at 24 h under SVS:
κ=0.03 for moderate ARDS and κ=0.29 for severe ARDS.
Of note, 27.6% (132/478) of patients categorised at
baseline as severe or moderate ARDS progressed with
usual care to mild ARDS or non-ARDS when assessed
under SVS, while 11.8% (36/305) of patients cate-
gorised as moderate ARDS by Berlin criteria progressed
to severe ARDS when assessed under SVS. Signiﬁcant
Table 2 Demographics, physiological and clinical
parameters at study entry in 478 patients with moderate/
severe ARDS
Variable Values
Age, years, median (IQR) 55 (40–70)
APACHE II score 21±7
Lung injury score 2.9±0.7
Tidal volume, mL/kg PBW 7.2±1.2
PEEP, cm H2O 9±3
Plateau pressure, cm H2O 26.5±6
FiO2 0.75±0.2
PaO2/FiO2, mm Hg 118±39
PaCO2, mm Hg 45±11
Causes of ARDS, n (%)
Pneumonia 176 (36.8)
Sepsis 144 (30.1)
Trauma 80 (16.7)
Aspiration pneumonia 60 (12.5)
Others 18 (3.8)
Number of organ failures 1.3±1.1
Hospital mortality, n (%) 202 (42.2)
ARDS, acute respiratory distress syndrome; PBW, predicted body
weight; PaO2/FiO2; ratio of arterial partial pressure of oxygen to
fraction of inspired oxygen; PEEP, positive end-expiratory
pressure.
Villar J, et al. BMJ Open 2015;5:e006812. doi:10.1136/bmjopen-2014-006812 3
Open Access
differences for lung injury score, PEEP, plateau pressure,
number of failing organs and VFDs were found in each
category (table 5). Patients who evolved to non-ARDS
were signiﬁcantly younger than the other categories.
Hospital mortality decreased 1.9–1.6-fold with every
stage of PaO2/FiO2 severity. The lower the PaO2/FiO2
category, the higher the hospital mortality: 69/103
(67%, 95% CI 57.5% to 75.5%) vs 104/243 (42.8%, 95%
CI 36.7% to 49.1%) vs 26/108 (24.1%, 95% CI 16.7% to
32.8%) vs 3/24 (12.5%, 95% CI 3.2% to 30%) for
severe, moderate, mild and non-ARDS categories,
respectively (p<0.000001) (table 6).
Our model of risk stratiﬁcation based on the measure-
ment of PaO2/FiO2 under SVS outperformed risk strati-
ﬁcation using baseline PaO2/FiO2 or non-standardised
PaO2/FiO2 at 24 h. The area under the ROC curve for
stratiﬁcation at baseline was 0.583 (95% CI 0.525 to
0.636), at 24 h without standardisation it was 0.605 (95%
CI 0.552 to 0.658), and at 24 h under SVS it was 0.693
(95% CI 0.645 to 0.742) (p<0.000001) (ﬁgure 2).
DISCUSSION
Our present investigation in a large population of con-
secutive patients with moderate and severe ARDS who
were managed with a low-VT strategy in the context of
two observational studies revealed that: (1) the value of
PaO2/FiO2 ratio at the time of ARDS diagnosis failed to
identify subgroups of patients with a distinct degree of
lung injury, and (2) a standardised ventilatory method
based on preset PEEP and FiO2 levels is more precise
than the use of PaO2/FiO2 at ARDS onset or after 24 h
of usual care in assessing risk stratiﬁcation of patients
with ARDS. Our study suggests that patients within an
identical PaO2/FiO2 range at baseline or after 24 h may
not have similar degrees of lung injury or prognosis. We
Table 4 Demographics, physiological and clinical parameters of 478 patients with ARDS categorised by the Berlin criteria
(baseline PaO2/FiO2)
Parameters
478 patients with moderate and severe ARDS (Berlin criteria)
Severe
n=173
Moderate
n=305 p Value
Age, year, median (IQR) 56 (41–71) 55 (39–68) NS
Lung injury score 3.0±0.6 2.9±0.6 NS
PEEP, cm H2O 10±3 9±3 NS
VT, mL/kg PBW 7.1±1.2 7.3±1.3 NS
Pplat, cm H2O 27±5 25.5±6 <0.01
FiO2 0.92±0.13 0.66±0.18 <0.0001
PaO2/FiO2, mm Hg 78±14 141±27 <0.0001
Number of organ failures 1.4±1.2 1.3±1.1 NS
VFDs, days, median (IQR) 0 (0–10) 6 (0–18) <0.01
Hospital mortality, n (%) 93 (53.7) 109 (35.7) 0.002
ARDS, acute respiratory distress syndrome; MV, mechanical ventilation; NS, non-significant; PaO2/FiO2, ratio of arterial partial pressure of
oxygen to fraction of inspired oxygen; PBW, predicted body weight; PEEP, positive end-expiratory pressure; Pplat, plateau pressure; VFDs,
ventilator-free days.
Table 3 Baseline characteristics of 478 survivors and non-survivors with ARDS
Variables
Values
Survivors
N=276
Non-survivors
N=202 p Value
APACHE II 19±6 23±7 <0.0001
Age, years, median (IQR) 49 (36–64) 64 (50–74) <0.0001
Gender, males/females, n (%) 193 (69.9)/83 (30.1) 141 (69.8)/61 (30.2) NS
VT, mL/kg PBW, mean±SD 7.2±1.2 7.3±1.1 NS
Plateau pressure, cm H2O, mean±SD 26±6 27±6 NS
PEEP, cm H2O, mean±SD 9±3 9±3 NS
FiO2, mean±SD 0.73±0.21 0.79±0.20 NS
PaO2/FiO2, mean±SD 120±39 114±39 NS
Total number of organ failures, mean±SD 1.2±1.0 1.5±1.2 0.003
Causes of ARDS, n (%)
Pulmonary 162 (58.7) 103 (51.0) NS
Non-pulmonary 114 (41.3) 99 (49.0)
ARDS, acute respiratory distress syndrome; NS, non-significant; PaO2/FiO2, ratio of arterial partial pressure of oxygen to fraction of inspired
oxygen; PBW, predicted body weight; PEEP, positive end-expiratory pressure; VT, tidal volume.
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found that there was a marked PaO2/FiO2 variability
within the ﬁrst 24 h of ARDS diagnosis since patients
could have the same range of PaO2/FiO2 but calculated
under different levels of ventilatory support.
If assessment of ARDS severity is of crucial import-
ance, it should be appropriate to set standardised rules
for quantifying the severity of lung injury. The Berlin
proposal of using the value of PaO2/FiO2 at the time of
ARDS onset does not mandate standardisation of PEEP
and FiO2 levels. The PaO2/FiO2 is generally calculated
under a wide range of applied PEEP and FiO2, and can
be easily manipulated by changing the PEEP and FiO2.
Thus, if the measurement of PaO2 is not standardised,
the calculated PaO2/FiO2 may mask the severity of the
underlying lung pathology in a substantial proportion of
patients. Although baseline PEEP could not predict
outcome,11 14 baseline FiO2 does predict mortality.
11 15
The key issue unmasked by our analyses is that many
patients with severe lung disease evolved with usual care
to less severe forms of lung injury within 24 h while
others evolved to more severe forms of ARDS, as clearly
demonstrated by the lack of concordance between the
Berlin criteria and data at 24 h under SVS. The use of
24 h non-standardised PaO2/FiO2 was also inferior to
PaO2/FiO2 assessment for risk stratiﬁcation under SVS
at 24 h. Since clinical practice introduces bias in the
assessment of lung injury severity, our study clearly sup-
ports that it is the standardisation of ventilatory settings
at 24 h that is crucial for appropriate stratiﬁcation.
Our model of risk stratiﬁcation supports the fact that all
cases of severe hypoxaemia are not ARDS. Patients
whose oxygenation status changes dramatically in 24 h
under a standardised assessment method would not be
expected to have severe generalised lung inﬂammation
as in ARDS, and should not be classiﬁed as ARDS.
Table 5 Demographics, physiological and clinical parameters of 478 patients with the acute respiratory distress syndrome
(ARDS) at 24 h of ARDS onset after being categorised by assessment of PaO2/FiO2 on PEEP≥10 cm H2O with FiO2≥0.5
Parameters
Classification at 24 h under standardised ventilator settings
Severe
n=103
Moderate
n=243
Mild
n=108
Non-ARDS
n=24 p Value
Age, year, median (IQR) 58 (41–69) 56 (43–71) 54 (36–70) 39 (28–62) 0.014
Lung injury score 3.3±0.5 3.0±0.7 2.3±0.6 2.3±0.5 <0.0001
PEEP, cm H2O 13±3 12±3 10±3 9±3 <0.0001
VT, mL/kg PBW 7.0±1.2 7.0±1.5 6.9±1.5 7.5±1.5 NS
Pplat, cm H2O 28±5 25±6 24±6 24±5 <0.0001
FiO2 0.94±0.10 0.73±0.18 0.58±0.16 0.54±0.09 <0.0001
PaO2/FiO2, mm Hg 78±14 145±28 242±26 357±50 <0.0001
Number of organ failures 2.5±1.5 1.9±1.4 1.5±1.3 1.0±1.2 <0.0001
VFDs, days, median (IQR) 0 (0–0) 0 (0–15) 15 (0–22) 22 (14–24) <0.0001
Hospital mortality, n (%) 69 (67) 104 (42.8) 26 (24.1) 3 (12.5) <0.000001
Values of lung injury score, PEEP, tidal volume, FiO2 and plateau pressure represent the mean values before assessing the patient under
standardised ventilator setting. Mean PaO2/FiO2 was calculated during standardised assessment.
MV, mechanical ventilation; NS, non-significant; PaO2/FiO2, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen; PBW,
predicted body weight; PEEP, positive end-expiratory pressure; Pplat, Plateau pressure; VFDs, ventilator-free days.
Figure 1 Flow diagram of the study. The percentages are a
proportion of the total patients initially classified as moderate
and severe, respectively. AECC, American-European
Consensus Conference; ARDS, acute respiratory distress
syndrome; PaO2/FiO2, ratio of arterial partial pressure of
oxygen to fraction of inspired oxygen; PEEP, positive
end-expiratory pressure; SVS, standardised ventilator setting.
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Our ﬁndings have implications for clinical trials
design and patient enrolment. ALI has a range of sever-
ity from mild pulmonary insult to full blown ARDS. The
assessment of PaO2/FiO2 at 24 h after ARDS diagnosis
on SVS can be used to insure a better categorisation of
patients by disease severity. As our data suggest, the use
of the Berlin criteria or the PaO2/FiO2 at 24 h under
non-standardised conditions is inadequate for enrolling
patients with similar degrees of lung injury into clinical
trials. The use of baseline or non-standardised PaO2/
FiO2 values for fast enrolment into therapeutic clinical
trials may be responsible for patient selection bias, as a
treatment that might beneﬁt a subgroup of patients with
ARDS is also tested in patients who are unresponsive to
the experimental treatment. Some clinicians are con-
cerned about a mandatory waiting period for reassess-
ment of oxygenation before enrolling patients with
ARDS into clinical trials.16 However, all trials performed
to date in ARDS have enrolled patients within 24–72 h
of ARDS onset17–22 and up to 7 days after meeting the
AECC criteria.23 24 It is possible that similar results
could be obtained if patients were assessed after 12 or
18 h of routine clinical care, but our study design pre-
cludes us to speculate further. It is well accepted that in
a high proportion of patients, lung function improves
dramatically within the initial 24 h of usual care. Also, it
is likely that within the initial 24 h, patients are not
stable when routine therapies (ie, ﬂuid resuscitation,
sedation, muscle paralysis, antibiotics, insulin, catechol-
amine, blood transfusion, body positioning, intravascular
catheterisation, repetitive and aggressive suctioning or
secretions, insertion of chest tubes, selection of the best
ventilatory pattern, etc) are implemented.
This study demonstrated that risk stratiﬁcation of
patients with ARDS based on PaO2/FiO2 ratios recorded
at ARDS onset or diagnosis (baseline) or measured
without standardising PEEP and FiO2 after 24 h of usual
care, is not clinically useful. If patients in a trial have a
low risk of the condition that the intervention is
hypothesised to prevent, the trial will not demonstrate
the efﬁcacy of the intervention, regardless of the trial
size.25 Stratiﬁcation of enrolled patients can reduce the
necessary sample size, since it makes larger treatment
effects easier to detect.26 That could explain why only
one randomised controlled trial in patients with ARDS
has been positive27 since the publication of the ARDS
net trial. In that study, only patients with a PaO2/FiO2
threshold that persisted after 12–24 h under a speciﬁc
level of PEEP and FiO2 were enrolled. Recent high-
frequency ventilation trials have been either ineffective
or worse than usual care,28 29 potentially due to a
patient selection bias: both trials enrolled patients based
on baseline PaO2/FiO2. These trials support the
Figure 2 Receiver operating curves for risk assessment
using the ratio of arterial partial pressure of oxygen to fraction
of inspired oxygen (PaO2/FiO2) ratio of each patient under
standardised ventilator setting (SVS) at 24 h, and compared
to risk stratification at ARDS onset (baseline) and at 24 h
(T24) without standardising the measurement of PaO2/FiO2
values.
Table 6 Mortality rates of 478 patients with ARDS when classified at baseline based on the values of PaO2/FiO2 at ARDS
onset (Berlin criteria), after 24 h of usual care and at 24 h under a SVS
Assessment
Mortality (%) by degree of severity
p ValueSevere Moderate Mild Non-ARDS
At ARDS onset (baseline)
Number of patients 173 305 – – 0.002
Number of deaths, (%) 93 (53.7) 109 (35.7)
After 24 h of usual care
Number of patients 100 289 83 6 0.064
Number of deaths, (%) 53 (53.0) 115 (39.8) 33 (39.8) 1 (16.7)
At 24 h under SVS
Number of patients 103 243 108 24 <0.000001
Number of deaths, (%) 69 (67.0) 104 (42.8) 26 (24.1) 3 (12.5)
ARDS, acute respiratory distress syndrome; PaO2/FiO2, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen; SVS,
standardised ventilator settings.
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importance of PaO2/FiO2 assessment after 24 h of
making the initial diagnosis of ARDS. If severe ARDS is
characterised by profound hypoxaemia that responds to
traditional management, our ﬁndings demonstrated that
a high rate of misclassiﬁcation occurred because patients
were not reassessed after 24 h of usual care when many
patients responded to a stepwise escalation of traditional
therapies. If patients are identiﬁed as severe ARDS by
the Berlin criteria only, they could be forced to receive
highly invasive and aggressive therapies that provide no
beneﬁt (useless) or could be harmful (worse than usual
care), since after 24 h of usual care a high percentage of
patients have milder forms of ARDS. We would recom-
mend attempting to enrol patients who met the Berlin
deﬁnition at ARDS onset but only randomising those
patients who sustained the desired level of injury after
24 h of usual care while conﬁrming established hypox-
aemia on SVS.
In an attempt to validate the modiﬁcation of the
AECC ARDS deﬁnition by the Berlin criteria, Hernu
et al30 and Caser et al31 found that neither deﬁnition was
able to identify subgroups with different levels of lung
injury based on non-standardised baseline PaO2/FiO2
values. Those studies reported that the Berlin criteria
were incapable of separating patients into distinct cat-
egories of severity with signiﬁcantly different mortalities.
Furthermore, a recent autopsy study revealed that the
Berlin criteria did not correlate with the presence of
diffuse alveolar damage in more than 50% of patients
categorised as moderate and severe ARDS.32 However,
this correlation improved signiﬁcantly only when
patients met PaO2/FiO2 criteria beyond 24 h of persist-
ence of ARDS criteria. Despite the fact that changes in
the applied FiO2 and PEEP induce profound variations
in PaO2/FiO2,
9 33 by leaving the assessment of PaO2/
FiO2 criteria essentially unchanged, the AECC deﬁnition
and the Berlin criteria are essentially identical.2 34 The
requirement of a minimum PEEP level of 5 cm H2O has
no impact on the deﬁnition9 since it is hard to conceive
that an patient with ARDS would be managed with
PEEP<5 cm H2O.
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Our study has several strengths. First, our study design
included all consecutive patients who met the criteria
for moderate and severe ARDS, so we believe that our
patients closely represented routine patients with ARDS.
Second, patients were enrolled in a multidisciplinary
network of teaching hospitals, not just one institution.
Third, our stratiﬁcation approach outperformed categor-
isation at baseline and categorisation at 24 h without
standardisation of the measurement of PaO2/FiO2. On
the other hand, we acknowledge a couple of limitations
to this study. First, we did not enrol patients with mild
ARDS under the Berlin criteria (PaO2/FiO2>200mmHg).
However, we do not believe that the exclusion of these
patients weakens our results. Those meeting criteria for
mild ARDS constitute a very heterogeneous group of
patients who are usually underdiagnosed, representing a
case-mix in which many do not require endotracheal
intubation and invasive MV. Also, since PaO2/FiO2
values in patients under non-invasive MV are not com-
parable with those on conventional MV, it is not clear
whether patients meeting criteria for mild ARDS on
non-invasive ventilation would meet those criteria after
intubation and conventional MV. However, we are conﬁ-
dent that no patients with mild ARDS were excluded
during our observational periods if they moved to a
more severe category, although we do not have data on
the precise number of these patients. Second, we cannot
expect our approach of risk stratiﬁcation to hold for
patients ventilated in a non-lung protective manner
since it is clear that ventilation with large VT and high
end-inspiratory plateau pressures causes ventilator-
induced lung injury in addition to the pre-existing
ARDS, and we do not expect our approach to predict
outcomes in this setting.
In conclusion, the stratiﬁcation of patients with ARDS
based on the value of PaO2/FiO2 ratio at the time of
ARDS diagnosis, as proposed by the Berlin criteria, or
based on the non-standardised value of PaO2/FiO2 at
24 h after usual clinical care, is not useful for assessing
severity of lung injury or for enrolling appropriate
patients with ARDS into clinical trials. Assessment of
ARDS should be a two-step process. The initial assess-
ment at ARDS onset followed by a second assessment at
24 h under SVS represents a better method for optimis-
ing risk stratiﬁcation of patients with ARDS. Since there
is no biomarker to identify patients as having ARDS or
to identify the severity of illness, we must continue to
search for methods to better deﬁne and stratify ARDS.
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